2025
Apr 18, 2025
23andMe Provides Update Regarding Court-Supervised Sale ProcessMar 26, 2025
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable LawMar 23, 2025
23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale ProcessMar 21, 2025
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab TestMar 3, 2025
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne WojcickiJan 31, 2025
23andMe Launches New Genetic Report on OsteoporosisJan 28, 2025
23andMe Special Committee Announces Exploration of Strategic AlternativesJan 28, 2025
23andMe Reports Third Quarter Fiscal Year 2025 Financial ResultsJan 8, 2025
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
2024
Nov 20, 2024
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & InflammationNov 12, 2024
23andMe Reports Second Quarter Fiscal Year 2025 Financial ResultsNov 11, 2024
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the FutureNov 7, 2024
CORRECTION - 23andMe to Report Q2 FY2025 Financial ResultsNov 7, 2024
23andMe to Report Q2 FY2025 Financial ResultsOct 30, 2024
23andMe Regains Compliance With Nasdaq Listing RequirementsOct 29, 2024
23andMe Appoints Three New Independent Directors to BoardOct 17, 2024
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the SouthOct 16, 2024
23andMe Announces Completion of 1-for-20 Reverse Stock SplitOct 11, 2024
23andMe Announces 1-for-20 Reverse Stock SplitOct 8, 2024
23andMe Announces Mathew Knowles as New Brand AmbassadorSep 25, 2024
23andMe Launches New Genetic Report on Likelihood of Frequent Emotional EatingSep 17, 2024
Independent Directors of 23andMe Resign from BoardSep 15, 2024
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 TrialSep 15, 2024
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 StudySep 12, 2024
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All PopulationsSep 3, 2024
23andMe to Present Updates on Clinical Immuno-oncology Programs 23ME-00610 and 23ME-01473 at ESMO Congress 2024Aug 28, 2024
Lemonaid Health Now Offering GLP-1 Medication Through Weight Loss Membership ProgramAug 8, 2024
23andMe Reports First Quarter Fiscal 2025 Financial ResultsAug 2, 2024
23andMe Special Committee responds to CEO’s take-private proposalAug 1, 2024
23andMe Announces CEO’s Take-Private ProposalJul 25, 2024
23andMe to Report Q1 FY2025 Financial ResultsJul 25, 2024
Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance ResearchJun 28, 2024
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker PanelJun 5, 2024
23andMe Launches New Genetic Report on Bipolar DisorderJun 4, 2024
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black CommunityJun 3, 2024
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual MeetingMay 29, 2024
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and historyMay 23, 2024
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial ResultsMay 14, 2024
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros PharmaceuticalsMay 9, 2024
23andMe to Report Q4 and Full Year FY2024 Financial ResultsApr 24, 2024
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApr 18, 2024
23andMe announces CEO’s intention to pursue a potential take-privateApr 5, 2024
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024Mar 20, 2024
23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6Mar 19, 2024
23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years AgoMar 6, 2024
23andMe Launches New Genetic Reports on Common Forms of CancerMar 5, 2024
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024Feb 7, 2024
23andMe Reports Third Quarter Fiscal 2024 Financial ResultsJan 31, 2024
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6Jan 30, 2024
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernayJan 24, 2024
23andMe to Report FY2024 Third Quarter Financial Results
2023
Dec 19, 2023
23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohortsNov 8, 2023
23andMe Reports Second Quarter Fiscal 2024 Financial ResultsNov 7, 2023
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health MembershipNov 6, 2023
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1Oct 31, 2023
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health DataOct 30, 2023
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSKOct 25, 2023
23andMe to Report FY2024 Second Quarter Financial ResultsSep 27, 2023
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual MeetingSep 14, 2023
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness ProgramAug 31, 2023
23andMe Granted New FDA Clearance to Report Additional BRCA VariantsAug 8, 2023
23andMe Reports FY2024 First Quarter Financial ResultsJul 25, 2023
23andMe to Report FY2024 First Quarter Financial ResultsJul 20, 2023
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed StatinJun 21, 2023
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic AttacksMay 25, 2023
23andMe Reports FY2023 Fourth Quarter and Full Year Financial ResultsMay 16, 2023
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health pictureMay 11, 2023
23andMe to Report FY2023 Fourth Quarter and Full Year Financial ResultsMay 9, 2023
23andMe Releases New Report Revealing Likelihood of Developing LupusMay 8, 2023
Reza Afkhami Joins 23andMe as Chief Corporate Development OfficerApr 14, 2023
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1Apr 11, 2023
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness ProgramMar 29, 2023
23andMe Publishes Inaugural Environmental, Social and Governance ReportMar 24, 2023
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular DiseaseMar 14, 2023
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023Mar 9, 2023
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized HealthcareFeb 28, 2023
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid MalignanciesFeb 22, 2023
23andMe to Present at Upcoming Investor ConferencesFeb 8, 2023
23andMe Reports FY2023 Third Quarter Financial ResultsJan 26, 2023
23andMe to Report FY2023 Third Quarter Financial Results
2022
Dec 1, 2022
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday SeasonNov 7, 2022
23andMe Reports FY2023 Second Quarter Financial ResultsNov 7, 2022
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual MeetingOct 27, 2022
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol MedicationOct 24, 2022
23andMe to Report FY2023 Second Quarter Financial ResultsOct 12, 2022
23andMe to Present at Upcoming Investor ConferencesOct 5, 2022
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual MeetingSep 19, 2022
Daniel Chu Joins 23andMe as Chief Product OfficerAug 8, 2022
23andMe Reports FY2023 First Quarter Financial ResultsJul 25, 2022
23andMe to Report FY2023 First Quarter Financial ResultsMay 26, 2022
23andMe Reports FY2022 Fourth Quarter and Full Year Financial ResultsMay 12, 2022
23andMe to Report FY2022 Fourth Quarter and Full Year Financial ResultsMar 15, 2022
23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual MeetingFeb 25, 2022
23andMe to Present at Cowen 42nd Annual Health Care ConferenceFeb 17, 2022
23andMe to Present at Citi’s 2022 Virtual Healthcare ConferenceFeb 10, 2022
23andMe Reports FY2022 Third Quarter Financial ResultsJan 27, 2022
23andMe to Report FY2022 Third Quarter Financial ResultsJan 18, 2022
23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology ProgramJan 10, 2022
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer MarkerJan 6, 2022
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
2021
Dec 28, 2021
23andMe Announces the Results of the Completed Redemption of All Outstanding WarrantsFeb 4, 2021
23andMe to Merge with Virgin Group’s VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics January 15, 2021 Medscape study in collaboration with 23andMe finds Primary Care Physicians are increasingly more comfortable with direct-to-consumer genetic health testingJan 15, 2021
Medscape study in collaboration with 23andMe finds Primary Care Physicians are increasingly more comfortable with direct-to-consumer genetic health testing
2020
2019
Oct 16, 2019
New 23andMe Health + Ancestry Service Customer Survey Conducted by M/A/R/CSep 30, 2019
23andMe Achieves ISO/IEC 27001:2013 CertificationJul 16, 2019
23andMe and Alnylam Collaborate on +MyFamily Program to Increase Awareness of TTR-Related Hereditary AmyloidosisApr 29, 2019
Michael J. Fox Foundation and 23andMe Launch Fox DENMar 10, 2019
23andMe Offers New Genetic Report on Type 2 DiabetesJan 22, 2019
23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Colorectal Cancer SyndromeJan 8, 2019
Lark Health and 23andMe Collaborate to Integrate Genetic Information in Two New Health Programs
2018
Oct 31, 2018
23andMe Granted the First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetic ReportsJul 25, 2018
GSK and 23andMe sign agreement to leverage genetic insights for the development of novel medicinesMar 6, 2018
23andMe Granted First FDA Authorization for Direct-to-Consumer Genetic Test on Cancer Risk
2017
Sep 18, 2017
National Survey Shows Strong Interest In DNA TestingSep 12, 2017
23andMe Raises $250 Million in Growth Financing Led by Sequoia CapitalAug 2, 2017
23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar DisordersMay 3, 2017
23andMe and German Pain Specialist Grünenthal Explore the Genetics of Pain to Help Identify New Treatments for PatientsApr 6, 2017
23andMe, Inc. Granted First FDA Authorization to Market Direct-to-Consumer Genetic Health Risk ReportsFeb 22, 2017
Celmatix and 23andMe Announce Launch of Fertility Research Community
2016
Oct 19, 2016
23andMe Launches Genotyping Services for Research Grant ProgramOct 13, 2016
23andMe, NIH Work to Reduce Health Research Disparities Among African AmericansSep 21, 2016
23andMe Offers $99 Genetic Ancestry ServiceSep 15, 2016
Nevada Population Health Study to Offer Free 23andMe Genetic Tests to CommunityJul 13, 2016
23andMe Launches New Genotyping Services for ResearchApr 5, 2016
New Effort by 23andMe Could Increase Diversity in Genetic ResearchMar 21, 2016
23andMe Enables Genetic Research for ResearchKit AppsFeb 2, 2016
Is Being a Morning Person in Your DNA?
2015
Dec 4, 2015
23andMe Genetic Service Now Fully Accessible to Customers in New York and MarylandOct 21, 2015
23andMe Launches New Customer Experience – Reports Include Carrier Status That Meet FDA Standards, Wellness, Traits, and AncestryOct 14, 2015
23andMe Raises $115 Million in Series E Financing Led by Fidelity Management & Research CompanySep 29, 2015
Shining a light on polycystic ovary syndromeAug 17, 2015
Veteran Genomics and Biotech Executive Dean Schorno, CPA, Joins 23andMe as Chief Financial Officer and Head of OperationsAug 11, 2015
23andMe Adds Drug Discovery Experts Dr. Erik Karrer, Ph.D. and Dr. Alice (Yu) Chen, Ph.D. to Growing Therapeutics GroupJul 14, 2015
Creative Designer Scott Andress Joins 23andMeJun 18, 2015
23andMe Genotypes One Millionth CustomerMay 5, 2015
23andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc.Apr 2, 2015
Bioinformatics Pioneer Robert Gentleman, Ph.D., Joins 23andMe Leadership TeamMar 19, 2015
23andMe Appoints Board Certified Genetic Counselor Erynn Gordon to 23andMe’s Management TeamMar 12, 2015
23andMe to Create Therapeutics Group, Appoints Scientific Luminary, R&D Executive Richard Scheller, Ph.D. to LeadMar 10, 2015
Researchers from Stanford University and 23andMe Discover Genetic Links to RosaceaFeb 26, 2015
23andMe Appoints Kate Black as Privacy Officer and Corporate CounselFeb 25, 2015
Study Finds Clues to Genetic Disorders in Children of Older MothersFeb 19, 2015
23andMe Granted Authorization by FDA to Market First Direct-to-Consumer Genetic Test Under Regulatory Pathway for Novel DevicesFeb 4, 2015
23andMe Study Uncovers the Genetics of Motion SicknessJan 12, 2015
23andMe Announces Collaboration with Pfizer Inc. to Conduct Genetic Research Through 23andMe’s Research PlatformJan 6, 2015
23andMe and Genentech to Analyze Genomic Data for Parkinson’s Disease
2014
Dec 18, 2014
23andMe Study Sketches Genetic Portrait of the United StatesAug 12, 2014
23andMe Announces Agreement with Pfizer Inc. to Research Genetics of Ulcerative Colitis and Crohn’s DiseaseJul 29, 2014
23andMe Scientists Receive Approximately $1.4 Million in Funding from the National Institutes of HealthJun 20, 2014
23andMe Appoints Angela Wonson Vice President of CommunicationsMay 12, 2014
23andMe Introduces HaploScore to Improve Detection of DNA Shared Between IndividualsApr 23, 2014
91 Percent of Americans Know Genetic Information Can Influence Their HealthApr 16, 2014
23andMe Appoints Dr. Jill Hagenkord Chief Medical OfficerApr 2, 2014
Health Care and Genomics Industry Veteran, Kathy Hibbs, Esq. Joins 23andMe as Chief Legal and Regulatory OfficerJan 28, 2014
23andMe Helps Identify 11 New Genetic Associations for Asthma-With-Hay Fever
2013
Dec 5, 2013
23ANDME, INC. PROVIDES UPDATE ON FDA REGULATORY REVIEWNov 25, 2013
23andMe Statement Regarding FDA Warning LetterSep 17, 2013
23andMe and Udacity Launch Introductory Human Genetics CourseAug 22, 2013
23andMe Conducts the First Genetic Study of Non-Syndromic Striae Distensae (Stretch Marks)Aug 5, 2013
23andMe Launches First National TV CampaignJul 1, 2013
23andMe And ALSPAC Identify 16 New Genetic Associations For Pollen, Dust-Mite and Cat AllergiesJun 11, 2013
23andMe Appoints Andy Page as PresidentApr 25, 2013
23andMe Aims to Close Genetics Literacy Gap Among Americans in Celebration of DNA DayMar 14, 2013
23andMe Identifies Multiple Genetic Factors Impacting Development Of Nearsightedness In Largest Ever Genome-Wide Association Study On MyopiaFeb 12, 2013
Study Shows Consumers Have Few Negative Reactions to the Results of Genetic Testing for Cancer Mutations
2012
Dec 20, 2012
23andMe Presents Top Ten Most Interesting Genetic Findings of 2012Dec 13, 2012
23andMe’s Ancestry Composition Reveals People’s Ancestral Origins Going Back 500 Years And MoreDec 11, 2012
23andMe Raises More Than $50 Million in New FinancingDec 4, 2012
23andMe Scientists Receive More Than $500,000 In Funding from the National Institutes of HealthNov 5, 2012
23andMe Demonstrates Comprehensive Research Capabilities at Annual Meeting of the American Society of Human GeneticsOct 16, 2012
23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership PositionsOct 15, 2012
23andMe Compares Family History and Genetic Tests for Predicting Complex Disease RiskSep 14, 2012
23andMe Opens Its API to DevelopersJul 30, 2012
23andMe Takes First Step Toward FDA ClearanceJul 10, 2012
23andMe Acquires CureTogether, Inc.Jul 3, 2012
23andMe Contributes to Genetic Discoveries Related to Breast Size and Breast CancerJul 2, 2012
23andMe Names Andy Page to Board of DirectorsJun 19, 2012
23andMe Contributes to Genetic Discoveries Related to Male Pattern BaldnessMay 11, 2012
23andMe Lowers Price Again, Ends SubscriptionsApr 20, 2012
Khan Academy and 23andMe Partner to Promote Genetics Education on DNA DayApr 9, 2012
23andMe Provides The Science Behind PBS Series “Finding Your Roots with Henry Louis Gates, Jr.” With Its Personal Genome Service®Apr 6, 2012
23andMe Identifies Five Significant Genetic Associations for Hypothyroidism with Web-Based Research PlatformFeb 21, 2012
Muhammad Ali Joins 23andMe In Search for Parkinson’s Disease CureFeb 14, 2012
Cleveland Clinic Joins 23andMe in the Search For Genetic Clues to Parkinson’s DiseaseJan 3, 2012
23andMe Presents Top Ten Most Interesting Genetic Findings of 2011
2011
Nov 3, 2011
Dr. Ruben Mesa Joins 23andMe’s Myeloproliferative Neoplasms Initiative as Scientific AdvisorOct 25, 2011
23andMe Discovers Genetic Variant That May Protect Those at High Risk for Parkinson’s DiseaseAug 17, 2011
23andMe Replicates Over 180 Genetic Associations with Web-Based Research PlatformAug 3, 2011
23andMe Launches Myeloproliferative Neoplasms Research InitiativeJul 5, 2011
23andMe Names Dr. Ashley Ledbetter Dombkowski Chief Business OfficerJun 23, 2011
23andMe Identifies Two Novel Genetic Associations with Parkinson’s Disease and Finds A Substantial Genetic Component for The DiseaseJun 15, 2011
23andMe Database Surpasses 100,000 UsersJan 25, 2011
23andMe Achieves Milestone in Building Sarcoma Research Community and Announces Appointment of Sarcoma Scientific Advisory CommitteeJan 11, 2011
23andMe Presents Top Ten Most Interesting Genetic Findings of 2010Jan 7, 2011
23andMe Announces Additional Investment in Series C Financing; Dr. Ashley Ledbetter Dombkowski of MPM Capital Joins 23andMe’s Board of Directors
2010
Dec 16, 2010
23andMe Receives Funding from the National Institutes of Health to Evaluate Web-Based Research on the Genetics of Drug ResponseNov 24, 2010
23andMe Announces Immediate Availability of Upgraded Genotyping Array, Now Testing Approximately One Million SNPsNov 9, 2010
23andMe Raises More Than $22 million in Series C FinancingJun 24, 2010
23andMe Makes New Discoveries in Genetics Using Novel, Web-based, Participant-driven MethodsJun 3, 2010
23andMe Enlists Informed Medical Decisions to Make Independent Genetic Counseling Services Available to Customers
2009
Oct 13, 2009
23andMe Tests NFL Players’ DNA for Athletic Genetic FactorsApr 27, 2009
23andMe and Palomar Pomerado Health Partner to Give PPH Members Access to Their Genetic InformationMar 31, 2009
23andMe Launches Free Online Community For Moms and Moms-to-BeMar 12, 2009
23andMe Launches Parkinson’s Disease Genetics InitiativeJan 28, 2009
23andMe and mondoBIOTECH Partner to Advance Research of Rare Diseases
2008
Dec 18, 2008
Silicon Valley Veterans Sarah Imbach and Larry Tesler Join 23andMe Management TeamDec 8, 2008
23andMe Announces Holiday Season Multi-Pack DiscountOct 30, 2008
TIME Magazine Names 23andMe’s Personal Genome Service 2008 Invention of the YearOct 2, 2008
23andMe Announces Breast Cancer InitiativeSep 9, 2008
23andMe and Ancestry.com Partner to Extend Access to Genetic Ancestry ExpertiseSep 9, 2008
23andMe Democratizes Personal GeneticsMay 29, 2008
23andMe Launches Consumer-Enabled Research Program to Actively Engage Individuals in Genetics ResearchMay 14, 2008
23andMe and The Parkinson’s Institute Announce Initiative to Advance Parkinson’s Disease ResearchJan 22, 2008
23andMe Launches Web-Based Personal Genome Service™ Outside U.S.